BioStock: Competitive landscape opens opportunities for Stayble Therapeutics

Almost everyone gets back pain at some point and for some the pain persists for a long time. In about 40 per cent of cases, chronic back pain is due to degenerative disc disease, and it is these patients that Stayble Therapeutics targets with the injection treatment STA363. There are other treatments for degenerative disc disease in development, but none of them treat the root causes of back pain in the same way as Stayble Therapeutics. 

Read the interview with Stayble Therapeutics CSO Anders Lehmann at biostock.se: 

https://www.biostock.se/en/2021/09/competitive-landscape-opens-opportunities-for-stayble-therapeutics/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se